Video

Dr. Sara Tolaney on Cabozantinib in Breast Cancer

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Sara M. Tolaney, MD, MPH, Instructor in Medicine, Harvard Medical School, Medical Oncologist, Clinical Investigator, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor aimed at mutations in MET, VEGFR2, and RET. It was recently approved for the treatment of metastatic medullary thyroid cancer and is being explored as a therapy for numerous tumor types, including breast cancer.

In a phase II randomized discontinuation trial, which Tolaney highlights, cabozantinib showed a 14% rate of objective tumor regression in patients with heavily pretreated metastatic breast cancer. There is some rationale, Tolaney says, to analyze cabozantinib in ER-positive breast cancer with bone metastases, due to impressive bone scans and bone pain responses in the trial.

Additionally, Tolaney states, there is reason to explore cabozantinib in patients with triple-negative breast cancer (TNBC) since MET, a target for cabozantinib, is often overexpressed to a higher degree in TNBC than in ER-positive breast cancer.

Related Videos
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD